HKSE · 6998.HK
Edding Genor Group Holdings Limited
HK$1.60+HK$0.03 (+1.59%)
Edding Genor Group Holdings Limited’s quoted price sits in the lower half of its reported 52-week range, 58.97% below the high.
Loading market information…
HKSE · 6978.HK · HKD
Stock price, earnings
Quote as of Oct 30, 2026, 05:54 AM UTC. Cached market data; not a live quote.
One-year closing-price history · HKD. Historical prices are not a forecast.
Immunotech Biopharm Ltd’s quoted price sits in the lower half of its reported 52-week range, 90.32% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Immunotech Biopharm Ltd’s next earnings report is currently expected on Mar 19, 2027. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Immunotech Biopharm Ltd’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Immunotech Biopharm Ltd operates as a biopharmaceutical firm specializing in cellular immunotherapy. Its primary activities involve the investigation, development, and market introduction of T cell-based immunotherapy solutions for various cancers within the People's Republic of China. The company's flagship product, EAL, is a multi-target cellular immunotherapy currently undergoing Phase II clinical trials for the purpose of preventing liver cancer recurrence after surgery. Furthermore, Immunotech Biopharm is conducting both preclinical and clinical research on EAL for its potential use in treating lung cancer, glioma, gastric cancer, and colorectal cancer. Other pipeline assets include the 6B11-OCIK injection, which is in Phase I trials for ovarian cancer; the CAR-T-19 injection product, targeting B-cell acute lymphoblastic leukaemia; and a range of TCR-T cell products designed for solid tumor treatment. Established in 2006, the company's main office is located in Beijing, China.
Latest available per-share figures in HKD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 06:13 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
HK$1.60+HK$0.03 (+1.59%)
Edding Genor Group Holdings Limited’s quoted price sits in the lower half of its reported 52-week range, 58.97% below the high.
HK$1.02HK$0.00 (0.0%)
SinoMab BioScience Limited’s quoted price sits in the lower half of its reported 52-week range, 53.42% below the high.
HK$2.00-HK$0.07 (-3.15%)
Zhaoke Ophthalmology Limited’s quoted price sits in the lower half of its reported 52-week range, 48.05% below the high.
HK$6.40HK$0.00 (0.0%)
Sunho Biologics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 21.95% below the high.
HK$2.20-HK$0.03 (-1.35%)
JW (Cayman) Therapeutics Co. Ltd’s quoted price sits in the lower half of its reported 52-week range, 47.37% below the high.
HK$0.97HK$0.00 (0.0%)
Brii Biosciences Limited’s quoted price sits in the lower half of its reported 52-week range, 48.95% below the high.
HK$3.80HK$0.00 (0.0%)
Wuhan YZY Biopharma Co Ltd’s quoted price sits in the lower half of its reported 52-week range, 54.76% below the high.
HK$2.51HK$0.00 (0.0%)
3D Medicines Inc.’s quoted price sits in the lower half of its reported 52-week range, 60.9% below the high.
